Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Increased by Aberdeen Group plc

Key Points

• Aberdeen Group plc has increased its stake in Sarepta Therapeutics by 42.1% during the first quarter, now owning 650,279 shares valued at approximately $41.7 million.
• Sarepta Therapeutics reported stronger-than-expected earnings, with an EPS of $2.02 for the quarter and a revenue of $611.09 million, exceeding analysts' expectations.
• Despite recent gains, analysts maintain a consensus rating of "Hold" for Sarepta Therapeutics, with a target price of $43.63.

Aberdeen Group plc increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 42.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 650,279 shares of the biotechnology company's stock after purchasing an additional 192,584 shares during the period. Aberdeen Group plc owned 0.66% of Sarepta Therapeutics worth $41,676,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in SRPT. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth approximately $30,000. Center for Financial Planning Inc. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth approximately $31,000. Pandora Wealth Inc. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth approximately $45,000. UMB Bank n.a. lifted its holdings in shares of Sarepta Therapeutics by 53.0% in the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 276 shares during the last quarter. Finally, Logan Capital Management Inc. bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth approximately $61,000. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $21.81 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -25.07 and a beta of 0.46. The stock's fifty day simple moving average is $19.75 and its 200 day simple moving average is $53.54. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $144.22.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%. The company's quarterly revenue was up 68.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.07 EPS. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on SRPT shares. Wolfe Research started coverage on Sarepta Therapeutics in a research report on Tuesday, June 17th. They issued a "peer perform" rating on the stock. Wall Street Zen upgraded Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Cantor Fitzgerald restated a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Oppenheimer upgraded Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and raised their target price for the company from $30.00 to $37.00 in a research report on Tuesday, July 29th. Finally, BMO Capital Markets raised their target price on Sarepta Therapeutics from $25.00 to $50.00 and gave the company a "market perform" rating in a research report on Tuesday, July 29th. Six analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $43.63.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.